drugset / Trial / NCT02623062

Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study

NCT02623062 ↗

Phase 3 Completed 644 enrolled Reckitt Benckiser Healthcare (UK) Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted in China to provide evidence for inclusion in applications to competent authorities that the Compound Sodium Alginate Oral Suspension sachet is effective in managing the symptoms of heartburn and acid regurgitation in patients with gastro-esophageal reflux disease (GERD).

Timeline

Start
2013-12
Primary completion
2016-03
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Compound Sodium Alginate Unknown 20 ml Oral